2 results
Approved WMOCompleted
Primary objective:To assess the effects of firibastat (QGC001) administered at 1000 mg orally (po) once daily (QD) on blood pressure (BP) over 12 weeksSecondary objectives:• To assess the safety of firibastat (QGC001) administered at 1000 mg po QD…
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.